Comparative Evaluation of Netarsudil and Latanoprost Ophthalmic Solutions to Assess Their Efficacy and Safety in Newly-Diagnosed Primary Open Angle Glaucoma Patients- A Randomized Controlled Trial - NI

Dr Rinky Thakur0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•Male or female patients aged >18years
•Patients with newly-diagnosed Primary open angle glaucoma by the treating physician with mean IOP >21 mmHg and <30 mmHg (measured by calibrated Goldmann applanation tonometer) in at least one eye at 10:00 AM. In case both eyes are diseased and fulfil the criteria, the worse eye is selected as the study eye. In case both eyes have equal IOP, the right eye is selected as the study eye.
•Patients with best corrected visual acuity of >6/60 in both eyes
•Willingness to follow study requirements including written informed consent

•Patients already on ocular hypotensive drugs
•Patients with mean IOP less than or equal to 21 mmHg
•Patients with mean IOP greater than or equal to 30 mmHg in either eye
•Patients with ocular infection or inflammation in either eye
•Patients with any active ocular disease in either eye other than Primary open angle glaucoma or with systemic disease that could interfere with study results
•History of ocular trauma, angle closure or narrow iridocorneal angles (including previous
•peripheral iridotomy)
•previous glaucoma incisional surgery or laser surgery or refractive surgery
•Central corneal thickness >600 micrometer
•Patients with any abnormality preventing reliable applanation tonometry of either eye
•Known hypersensitivity to or contraindications to study drugs
•Women of childbearing potential who are pregnant, nursing or planning a pregnancy

发起方

Dr Rinky Thakur